Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
13.98
-0.15 (-1.06%)
At close: Apr 17, 2026, 4:00 PM EDT
13.95
-0.03 (-0.21%)
After-hours: Apr 17, 2026, 7:42 PM EDT
TNXP Revenue
In the year 2025, Tonix Pharmaceuticals Holding had annual revenue of $13.11M with 29.85% growth. Tonix Pharmaceuticals Holding had revenue of $5.39M in the quarter ending December 31, 2025, with 108.75% growth.
Revenue (ttm)
$13.11M
Revenue Growth
+29.85%
P/S Ratio
15.15
Revenue / Employee
$92,303
Employees
142
Market Cap
198.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.11M | 3.01M | 29.85% |
| Dec 31, 2024 | 10.09M | 2.33M | 29.94% |
| Dec 31, 2023 | 7.77M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.07M |
| Precision BioSciences | 34.26M |
| ProQR Therapeutics | 19.19M |
| Caribou Biosciences | 11.16M |
| Whitehawk Therapeutics | 7.15M |
| Korro Bio | 6.39M |
TNXP News
- 4 days ago - Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development - GlobeNewsWire
- 19 days ago - Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 - GlobeNewsWire
- 24 days ago - Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain - GlobeNewsWire
- 27 days ago - Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 - GlobeNewsWire
- 4 weeks ago - Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 - GlobeNewsWire
- 4 weeks ago - Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 5 weeks ago - Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch - Benzinga
- 5 weeks ago - Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - GlobeNewsWire